Dorra Pharma Awarded the "Certificate of Export Commodity Brand" And Selected as a Customs Sample Enterprise

發(fā)布時間： 2023-12-01 閱讀：537次

分享

Recently, Dorra Pharma has received two major honors: the Certificate of Export Commodity Brand issued by the China Council for the Promotion of International Trade (CCPIT), and selection into the China Customs Sample Enterprise Directory. These honors not only recognize Dorra Pharma's outstanding performance and continuous growth strength in the industry but also reflect the influence of the Dorra brand in the international market.

Awarded the "Certificate of Export Commodity Brand"

Dorra Pharma has always adhered to a core business philosophy of enhancing corporate and customer value. It persistently focuses on independent R&D as the driving force and maintains a business development policy supported by production, marketing, and quality assurance. Dorra Pharma successfully passed the joint certification established by the China Chamber of Commerce for Import and Export of Medicines & Health Products and CCPIT Trade Promotion Center, receiving the "Certificate of Export Commodity Brand".

The CCPIT Commercial Certification Center evaluates export brands of enterprises based on the group standard T/CCPITCSCO15-2023 "Export Commodity Brand Evaluation Specification". The evaluation covers eight dimensions: R&D innovation capability, international certification, market recognition, intellectual property protection, global operational credit system, social evaluation, and departmental penalties. Winning the Certificate of Export Commodity Brand is not only an affirmation of Dorra Pharma's international competitiveness but also a significant driving force for us to continue expanding the international market and improving global brand awareness. We will take this opportunity to continue to adhere to innovation-driven strategies, strengthen international cooperation, and commit to providing more high-quality products and comprehensive services.

Selected as a Customs Sample Enterprise

Recently, the General Administration of Customs of China released an important announcement to improve the accuracy of judgments on export situations and to serve the development of the country's goods trade. The Administration selected some export enterprises to collect information about their orders, confidence, and costs for compiling the "China Foreign Trade Export Leading Index". In this new round of sample enterprise selection, Dorra Pharma was chosen as a sample enterprise. This honor not only reflects Dorra Pharma's outstanding performance in the industry but also high recognition of its stable and continuous growth in export performance.

The General Administration of Customs adopted strict selection criteria for sample enterprises, including consistent export record growth from 2019 to 2021 and an export amount exceeding 38 million RMB in 2021. This selection reflects a comprehensive consideration of the company's stability, sustainability, and representativeness. A total of 3118 enterprises were selected in this round, covering 42 direct customs, including 78 enterprises from Nanjing. Most of the selected enterprises are state-owned enterprises, and Dorra Pharma, as a private enterprise, stood out among many export companies, demonstrating our leading position in the pharmaceutical industry and growing market influence.

Looking Forward

In the future, Dorra Pharma will continue to adhere to the principle of enhancing corporate and customer value, continuously improve product and service levels, and strive to gain wider recognition in the global pharmaceutical industry, creating more valuable products for life and health!